RXRui Xi

Rui Xi

*This is an algorithmically generated author record based on publicly available information.

Rui Xi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A PIB-Oriented Elliptic Beam Quality Calculation Based on Energy Distribution

    by Liu Yubo, Dai Qiang, Xi Rui, Tian Bowen

    The precise assessment of beam quality is a fundamental element in the design and practical applications of lasers. Conventional techniques relying on optical instruments or image processing, primarily centered on circular spot analysis, encounter inherent limitations. This study addresses the pressing need for an enhanced, user-centric methodology to compute the quality factor accurately, $\beta$ . Motivated by the shortcomings of established methods, particularly in dealing with intricate spot shapes and adhering to Power in the Bucket (PIB) requirements, our approach integrates image processing and computer vision for $\beta$ computation. Our method commences with image preprocessing for noise reduction and precise cropping, followed by an orientation gradient to rectify skewness. This is coupled with an integration step for initial beam width estimation, culminating in the derivation of $\beta$ Simultaneously, we introduce an innovative Ellipse Detection algorithm to mitigate spot deformation interference. Additionally, we devise a beamwidth tuning algorithm incorporating a bucket-type data structure to meet PIB requirements swiftly. Compared to traditional techniques, the results exhibit marked superiority in accuracy, computational speed, and user-friendliness. This novel approach presents a promising alternative for laser beamwidth determination, showcasing its potential for widespread adoption in practical applications.

  • Dasatinib protects against acute respiratory distress syndrome via Nrf2‐regulated M2 macrophages polarization

    by Zishuang Liu, Shanshan Chen, Xinfeng Zhang, Fangfang Liu, Kai Yang, Ge Du, Xi Rui

    Dasatinib, a tyrosine kinase inhibitor, has a protective effect on experimental acute respiratory distress syndrome (ARDS). This study investigated the effect and mechanism of dasatinib in ARDS. C57BL/6 mice were administered with dasatinib (1 and 10 mg/kg) after lipopolysaccharide (LPS) treatment to evaluate the effect of dasatinib on white blood cells (WBC), neutrophils, lymphocytes and macrophages in bronchoalveolar lavage fluid (BALF). The levels and mRNA expressions of inflammation‐related cytokines in lung tissues and RAW 264.7 cells were detected by enzyme‐linked immunosorbent assay and quantitative real‐time PCR, respectively. The protein expressions of nuclear factor E2‐related factor 2 (Nrf2) and heme oxygenase 1 (HO1) were determined by Western blot. MTT assay was performed to detect the viability of RAW 264.7 cell. Rescue experiments were used to assess the effect of Nrf2 silencing on the LPS‐ and dasatinib‐treated mice. Under LPS treatment, levels of the WBC, neutrophils, lymphocytes and macrophages in BALF and mRNA expressions of IL‐6, TNF‐α and IL‐10 as well as expression of iNOS were increased, but the expression of arginase‐1 was inhibited, while no obvious changes of the protein expressions of Nrf2 and HO1 were observed. Dasatinib partially reversed the effects of LPS above, and further promoted the mRNA expression of IL‐10 and the protein expressions of Nrf2 and HO1, while Nrf2 silencing counteracted the effect of dasatinib. Dasatinib induced the polarization of M2 subtype of macrophages and alleviated LPS‐induced ARDS through activating Nrf2 signaling pathway, which may provide a new strategy for the treatment of ARDS.


  • Electrodeposition of ZnO nanorods onto GaN towards enhanced H2S sensing

    by Chao Wang, Lu-Jia Wang, Long Zhang, Rui Xi, Hui Huang, Shao-Hui Zhang, Ge-Bo Pan


  • Open Access

    Elevated Serum Cyclophilin B Levels Are Associated with the Prevalence and Severity of Metabolic Syndrome

    by Hang Zhang, Qin Fan, Hongyang Xie, Lin Lu, Rong Tao, Fang Wang, Rui Xi, Jian Hu, Qiujing Chen, Weifeng Shen, et al.

    Objective: Inflammation plays a central role in the pathogenesis of metabolic syndrome (MetS). Cyclophilin B (CypB) can be constitutively secreted in response to inflammatory stimuli and oxidative stress, participating in tissue or systemic inflammation. We investigated the relationship between CypB and MetS in both humans and mice. Methods: Serum CypB levels were determined in 211 subjects with MetS and 292 subjects without MetS (non-MetS) (133 healthy controls and 159 high-risk subjects with one to two MetS components). Additionally, CypB expression in metabolic organs was examined in mice fed with high-fat diet (HFD) and genetically obese (ob/ob) mice. Results: Serum CypB level was significantly higher in MetS subjects compared with both groups of non-MetS subjects (193.80 ± 83.22 vs. 168.38 ± 65.01 vs. 124.26 ± 47.83 ng/mL, P < 0.001). Particularly, serum CypB level was significantly higher in subjects with hypertension, central obesity, diabetes mellitus or hyperglycemia, elevated levels of triglycerides, or reduced levels of high-density lipoprotein than in those without. Moreover, CypB was positively associated with the number of MetS components (r = 0.404, P < 0.001), indicating that a higher serum CypB level reflected more severe MetS. Multivariate regression revealed that a one SD increase in CypB was associated with an odds ratio of 1.506 (1.080–2.101, P = 0.016) for MetS prevalence after adjusting for age, gender, conventional risk factors, and medication. Stratified analyses by age and gender demonstrated that subjects >60 years old with higher CypB levels were more likely to have MetS, and the risk for MetS was higher and more significant in women compared with men. Additionally, CypB expression levels were lower at baseline and dramatically enhanced in metabolic organs (such as the liver) and visceral and subcutaneous adipose tissue from HFD-induced obese mice and ob/ob mice. Conclusion: Increased CypB levels were significantly and independently associated with the presence and severity of MetS, indicating that CypB could be used as a novel biomarker and clinical predictor of MetS.